文献速递银屑病与炎症性皮肤病皮肤感染

IL-23与IL-17抑制剂相对TNF抑制剂感染风险的人群研究

Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors - A population-based study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-07-19

该全球队列研究比较银屑病患者使用IL-23i或IL-17i与TNFi的26种感染风险。经倾向评分匹配后,IL-23i和IL-17i均与多种感染风险降低相关,IL-23i关联中耳炎、脑炎、带状疱疹、HBV再激活、CMV、流感及寄生虫病风险降低,IL-17i关联肺炎、败血症、上呼吸道感染、带状疱疹、HBV/HCV再激活、CMV、EBV、流感及寄生虫病风险降低。

要点

  • IL-23i相比TNFi与带状疱疹(HR 0.58)、HBV再激活(HR 0.24)、流感(HR 0.52)等风险降低相关。
  • IL-17i相比TNFi与肺炎(HR 0.76)、上呼吸道感染(HR 0.84)、带状疱疹(HR 0.79)等风险降低相关。
  • 对易感感染的患者,IL-23i和IL-17i可能优于TNFi。

核心结论

  • 与TNFi相比,IL-23i和IL-17i与多种感染性疾病风险降低相关。
  • 对感染易感性患者,这些药物可能更受青睐。

研究设计与样本

  • 全球队列研究,包含两个分析:IL-23i新使用者(n=5272)对比TNFi(n=5272);IL-17i新使用者(n=15160)对比TNFi(n=15160)。
  • 采用倾向评分匹配优化组间可比性,比较26种感染风险。

主要发现

  • IL-23i组相比TNFi组:中耳炎HR 0.66(95%CI 0.44-0.97)、脑炎HR 0.18(95%CI 0.04-0.78)、带状疱疹HR 0.58(95%CI 0.41-0.82)、HBV再激活HR 0.24(95%CI 0.12-0.47)、CMV HR 0.25(95%CI 0.07-0.86)、流感HR 0.52(95%CI 0.38-0.71)、寄生虫病HR 0.78(95%CI 0.64-0.95)。
  • IL-17i组相比TNFi组:肺炎HR 0.76(95%CI 0.68-0.85)、败血症HR 0.84(95%CI 0.72-0.97)、上呼吸道感染HR 0.84(95%CI 0.77-0.92)、带状疱疹HR 0.79(95%CI 0.67-0.92)、HBV再激活HR 0.59(95%CI 0.46-0.76)、HCV再激活HR 0.71(95%CI 0.57-0.88)、CMV HR 0.58(95%CI 0.36-0.93)、EBV HR 0.38(95%CI 0.19-0.75)、流感HR 0.70(95%CI 0.61-0.81)、寄生虫病HR 0.80(95%CI 0.72-0.88)。

临床怎么用

  • 对于有感染易感性的银屑病患者,IL-23i和IL-17i可能较TNFi更优先选择。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The risk of infections among patients with psoriasis undergoing interleukin (IL)-23 inhibitors (IL-23i) and IL-17 inhibitors (IL-17i) is yet to be exhaustively determined. OBJECTIVE: To assess the risk of infectious complications in patients with psoriasis managed by IL-23i and IL-17i with tumour necrosis factor inhibitors (TNFi) as a comparator. METHODS: A global cohort study comprised two distinct analyses comparing patients with psoriasis under different therapeutic modalities; (i) new users of IL-23i (n = 5272) versus TNFi (n = 5272) and (ii) new users of IL-17i (n = 15,160) versus TNFi (n = 15,160). Study groups were compared regarding the risk of 26 different infections. Propensity score matching was conducted to optimize between-group comparability. RESULTS: Patients under IL-23i had a lower risk of otitis media (HR, 0.66; 95% CI, 0.44-0.97), encephalitis (HR, 0.18; 95% CI, 0.04-0.78), herpes zoster (HZ; HR, 0.58; 95% CI, 0.41-0.82), hepatitis B virus (HBV) reactivation (HR, 0.24; 95% CI, 0.12-0.47), cytomegalovirus (HR, 0.25; 95% CI, 0.07-0.86), influenza (HR, 0.52; 95% CI, 0.38-0.71) and parasitic diseases (HR, 0.78; 95% CI, 0.64-0.95). IL-17i was associated with a decreased risk of pneumonia (HR, 0.76; 95% CI, 0.68-0.85), septicaemia (HR, 0.84; 95% CI, 0.72-0.97), upper respiratory tract infection (HR, 0.84; 95% CI, 0.77-0.92), HZ (HR, 0.79; 95% CI, 0.67-0.92), HBV (HR, 0.59; 95% CI, 0.46-0.76) and hepatitis C virus (HR, 0.71; 95% CI, 0.57-0.88) reactivation, cytomegalovirus (HR, 0.58; 95% CI, 0.36-0.93), Epstein-Barr virus (HR, 0.38; 95% CI, 0.19-0.75), influenza (HR, 0.70; 95% CI, 0.61-0.81) and parasitic diseases (HR, 0.80; 95% CI, 0.72-0.88). CONCLUSION: Compared with TNFi, IL-23i and IL-17i are associated with decreased risk of several infectious diseases. These agents might be preferred in patients with susceptibility to infections.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Kridin K, Zirpel H, Mruwat N, et al. Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors - A population-based study. J Eur Acad Dermatol Venereol. 2023. PMID: 37466275. doi:10.1111/jdv.19328

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。